Peginterferon α-2a and ribavirin versus peginterferon α-2a monotherapy in early virological responders and peginterferon α-2a and ribavirin versus peginterferon α-2a, ribavirin and amantadine triple therapy in early virological nonresponders: The SMIEC II trial in naïve patients with chronic hepatitis C

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 7, 2008, Pages 680-687

  Angelico, Mario ^a   Koehler Horst, Beate ^a   Piccolo, Paola ^a,b   Angelico, Francesco ^c   Gentile, Silvia ^b   Francioso, Simona ^a   Tarquini, Pierluigi ^g   Vecchia, Roberto Della ^h   Ponti, Laura ⁱ   Pilleri, Giampaolo ⁱ   Barlattani, Angelo ^d   Grieco, Antonio ^e   Soccorsi, Francesco ^f   Guarascio, Paolo ^f   Demelia, Luigi ^j   Sorbello, Orazio ^j   Rossi, Zaccaria ^k   Forlini, Giuseppe ^k   Zaru, Salvatore ^l   Bandiera, Franco ^l  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d S Giacomo General Hospital   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f S Camillo General Hospital   (Italy)

^g Teramo General Hospital   (Italy)

^h UNIVERSITY OF CHIETI   (Italy)

ⁱ Cagliari General Hospital   (Italy)

^j DEPARTMENT OF RADIOLOGY   (Italy)

^k Albano Laziale General Hospital   (Italy)

^l Sassari General Hospital   (Italy)

more..

Author keywords

Amantadine; Antiviral treatment; Chronic hepatitis C; Early virological response; Sustained virological response

Indexed keywords

AMANTADINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ADD ON THERAPY; ADULT; AGED; ANAPHYLAXIS; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DERMATITIS; DRUG DOSE REDUCTION; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; IRRITABILITY; JAUNDICE; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STANDARD; THROMBOCYTOPENIA; THYROTOXICOSIS; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; AGE; BLOOD; DRUG COMBINATION; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AMANTADINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 62149152106     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282f5196c     Document Type: Article

References (38)

1. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
3. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Int Med 2004; 140:346-357.
4. Gaeta GB, Precone DF, Felaco FM, Bruno R, Spadaro A, Stornaiuolo G, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in the 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16:1633-1639.
5. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al.; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
6. Smith SR, Wahed AS, Kelley SS, Conjeevaram HS, Robuck PR, Fried MW. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother 2007; 41:1116-1123.
7. Davis GL, Wong JB, McHutchinson JG, Manns MP, Harvey J, Albrecht J, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
8. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 2004; 53:15-18.
9. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
10. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. New Engl J Med 2005; 352:2609-2617.
11. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97-103.
12. Zeuzem S, Pawlotsky J-M, Lukasievicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol 2005; 43:250-257.
13. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4:3021-3024.
14. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993; 67:5585-5594.
15. Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42:1681-1687.
16. Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, et al. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32:835-841.
17. Younossi ZM, Mullen KD, Zakko W, Hodnick S, Brand E, Barnes DS, et al. A randomised, double-blind controlled trial of interferon alfa-2b and ribavirin vs. interferon alfa-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy. J Hepatol 2001; 34:128-133.
18. Mangia A, Minerva N, Annese M, Leandro G, Villani MR, Santoro R, Carretta V. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001; 33:989-993.
19. Teuber G, Berg T, Naumann U, Raedle J, Brinkmann S, Hopf U, et al. Randomized, placebo-controlled, double-blind trial with interferon-alfa with and without amantadine sulfate in primary interferon-alfa nonresponders with chronic hepatitis C. J Viral Hepat 2003; 8:276-283.
20. Tabone M, Laudi C, Delmastro B, Biglino A, Andreoni M, Chieppa F, et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol 2001; 35:517-530.
21. Caronia S, Bassendine MF, Barry R, Mills P, Naoumov N, Fox R, et al.; UK Amantadine Study Group. Interferon plus amantadine versus interferon alone in the treatment of näive patients with chronic hepatitis C: a UK multicentre study. J Hepatol 2001; 35:512-516.
22. Helbling B, Stamenic I, Viani F, Gonvers JJ, Dufour JF, Reichen J, et al. Investigators of the Swiss Association for the Study of the Liver. Hepatol 2002; 35:447-454.
23. Baisini O, Gracielle Pigozzi M, Benini F, Stellini R, Reggiani A, Quattrocchi D, et al. A randomised, open label, controlled trial on the effect of interferon and amantadine compared with interferon alone for treatment of chronic hepatitis C. Hepatol Res 2003; 26:167-173.
24. Nakamura H, Uyama H, Enomoto H, Kishima Y, Yamamoto M, Yoshida K, et al. The combination therapy of interferon and amantadine hydrochloride in patients with chronic hepatitis C. Hepatogastroenterology 2003; 50: 222-226.
25. Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, Martin LM. Pegylated interferon alfa-2b, ribavirin and amantadine for chronic hepatitis C. Digestive Diseases and Sciences 2005; 50:970-975.
26. Jubin R, Murray MG, Howe AY, Butkiewicz N, Hong Z, Lau JY, et al. Amantadine and rimantadine have no direct inhibitory effects against hepatitis C viral protease, helicase, ATPase, polymerase, and internal ribosomal entry site-mediated translation. J Infect Dis 2000; 18:331-334.
27. Craxi A, Lo Iacono O. Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck? J Hepatol 2001; 35:527-530.
28. Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, et al. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol 2004; 40:478-483.
29. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32:630-663.
30. Carlsson T, Lindahl K, Schvarcz R, Wejstal R, Uhnoo I, Shev S, et al. HCV-RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin. J Viral Hepat 2000; 7:409-413.
31. Adinolfi LE, Utili R, Tonziello A, Ruggiero C. Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial. Gut 2003; 52:701-705.
32. Younossi ZM, Mullen KD, Hodnick S, Barnes DS, Carey WD, McCullough AC, Easley K. Triple combination of interferon alpha-2b, ribavirin and amantadine treatment of chronic hepatitis C. J Clin Gastroenterol 2003; 36:427-430.
33. Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology 2003; 37:1359-1367.
34. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, Pockros PJ. Prognostic factors and early predictability of sustained virological response with peginterferon alfa-2a (40 kDa). J Hepatol 2002; 37: 500-506.
35. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426-1432.
36. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680.
37. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33:433-438.
38. Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005; 12:292-299.